Tag: Neffy™ (ARS-1)
FDA Accepts New Drug Application for Nasal Epinephrine Spray Treatment for...
If approved, acceptance targeted for mid-2023.
They’re Coming: Needle-Free Emergency Epinephrine Options Currently in Trials
For some, the needle is a barrier to administration but alternatives are on the horizon.
CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...
The market for epinephrine delivery may expand to include non-needle alternatives next year.
Intranasal Epinephrine to Take Center Stage at 2022 AAAAI Annual Meeting
Emergency epinephrine without the jab makes strides.
Emergency Epinephrine Nasal Spray Takes Final Step Toward Approval in EU
A needle-free option for administration of epinephrine is on the horizon.
ARS Pharmaceuticals Announces New Patent on ARS-1 (Epinephrine Nasal Spray)
Intranasal delivery of emergency epinephrine takes another step closer to becoming a reality.
Study: Intranasal Epinephrine Absorbed Faster Than Injection and Even Better with...
Study compared absorption of epinephrine via nasal spray to that of intramuscular injection.
ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI...
Neffy™ (formally ARS-1) was fast-tracked by the FDA in 2019 as an intranasal alternative to epinephrine auto-injectors.
FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray
Company provides a novel means of administering emergency epinephrine.
